ABCL Q4 2025 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+788.2% YoY

Gross Profit

$45M100.0% margin

Operating Income

-$29M-63.7% margin

Net Income

-$9M-19.9% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+400.9%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$45M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$216M

Stockholders' Equity

$1.1B

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$5M	+788.2%
Gross Profit	$45M	$5M	+788.2%
Operating Income	-$29M	-$73M	+60.7%
Net Income	-$9M	-$34M	+73.9%

Revenue Segments

License

$36M82%

Research Fees

$8M18%